Proactive Investors - Run By Investors For Investors

Allergy Therapeutics teams up with Ergomed to take its anti-allergy tablets through the clinic

Allergy already has injectable vaccines for dust mites and tree and grass pollen, but it has brought in Ergomed to take the tablet formulations through clinical trials
woman with allergy
The tablets have been available in some European countries for a little while but only on a ‘named-patient basis’

Allergy vaccine maker Allergy Therapeutics plc (LON:AGY) has teamed up with fellow AIM company Ergomed Plc (LON:ERGO) to progress the clinical development of three of its OralVac immunotherapy products.

Under the terms of the co-development collaboration agreement, Ergomed will take the treatments for dust mite, tree pollen and grass pollen allergies through the clinic.

READ: Ergomed hopes to have PeproStat on the market by 2020 as it sails through Phase II trials

The development, which is scheduled to last for seven years, will kick off next year with a phase I study in the dust mite OralVac tablet.

Allergy Therapeutics already has injectable vaccines for those three allergies but wants to broaden its offering to cater for patients who don’t like needles and would prefer a pill.

The oral formulation has been available for more than two decades in Germany and other European countries but on a ‘named-patient basis’, which means doctors will only prescribe them in special cases.

Ergomed will receive a fee for conducting the clinical development activities although it will also be expected to stump to contribute some of the development costs.

In return, the company will receive future tiered royalties for each product once the first phase II study has been completed.

"We are pleased to announce this co-development programme with Ergomed, which is aimed at strengthening our product portfolio across Europe in a risk-sharing fashion,” said Allergy Therapeutics chief executive Manuel Llobet.

READ: Allergy Therapeutics - strong financial showing, solid cash position, progress in the clinic

“Ergomed has over 20 years of experience in clinical development and significant expertise in the allergy field, and are thus ideally placed to support us in the progression of our OralVac products.”

Ergomed executive vice chairman Miroslav Reljanovic added: “We are excited to join in the further development of these products which have established an important presence in the market.

“Ergomed has extensive experience in conducting clinical research in the field of allergy therapies, and so this is a natural therapy area for our next co-development project.”

Allergy shares rose 3% to 29p early on Tuesday, while Ergomed edged 0.5% higher to 185p.

View full AGY profile View Profile

Allergy Therapeutics PLC Timeline

Related Articles

blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
Woman sneezing
September 27 2018
"We look forward to the exciting developments in our early pipeline planned for 2019, and we expect to continue to grow our European business while progressing towards US and German registration for our lead products," said company chairman, Peter Jensen
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use